Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TAS-103 dihydrochloride (BMS-247615 dihydrochloride) is a novel anticancer agent targeting both topoisomerase (Topo) I and Topo II.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 9,000 | |||
5 mg | 在庫あり | ¥ 20,500 | |||
10 mg | 在庫あり | ¥ 30,500 | |||
25 mg | 在庫あり | ¥ 66,000 | |||
50 mg | 在庫あり | ¥ 98,500 | |||
100 mg | 在庫あり | ¥ 147,000 |
説明 | TAS-103 dihydrochloride (BMS-247615 dihydrochloride) is a novel anticancer agent targeting both topoisomerase (Topo) I and Topo II. |
In vitro | The in vitro antitumor effects of TAS-103 were compared with those of other known Topo I and Topo II inhibitors. TAS-103 inhibited DNA synthesis more strongly than RNA and protein synthesis, and induced an increase of cell population in the S-G2/M phase. The cytotoxicity of TAS-103 was strongest against S-phase cells, but its cell cycle phase specificity was not clear, and depended on drug concentration and exposure time. The cytotoxicity of TAS-103 (IC50: 0.0030-0.23 microM) against various tumor cell lines was much stronger than that of VP-16 and comparable to that of SN-38. The cytotoxicity of TAS-103 seemed to be more related to the amount of protein-DNA complexes than to the accumulation of TAS-103 in the cells. P-Glycoprotein (P-gp)-mediated MDR, CDDP-resistant and 5-FU-resistant cell lines did not show cross-resistance to TAS-103. Although PC-7/CPT cells bearing a Topo I gene mutation showed cross-resistance to TAS-103, the sensitivity of P388/CPT, HT-29/CPT and St-4/CPT cells, showing decreased Topo I expression, was not changed. KB/VM4 and HT-29/Etp cells, showing decreased Topo II expression, were slightly cross-resistant to TAS-103. These results suggest that TAS-103 may act as an inhibitor of both Topo I and Topo II at the cellular level[1]. |
別名 | TAS-103 (dihydrochloride), BMS-247615 dihydrochloride |
分子量 | 406.31 |
分子式 | C20H21Cl2N3O2 |
CAS No. | 174634-09-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (123.06 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TAS-103 dihydrochloride 174634-09-4 DNA Damage/DNA Repair Topoisomerase TAS-103 TAS 103 inhibit TAS 103 dihydrochloride TAS-103 Dihydrochloride TAS-103 (dihydrochloride) Inhibitor TAS103 dihydrochloride BMS-247615 Dihydrochloride TAS103 Dihydrochloride TAS103 BMS-247615 BMS 247615 BMS-247615 dihydrochloride BMS 247615 Dihydrochloride TAS 103 Dihydrochloride BMS247615 BMS247615 Dihydrochloride inhibitor